168 related articles for article (PubMed ID: 37939020)
21. Saponin 1 induces apoptosis and suppresses NF-κB-mediated survival signaling in glioblastoma multiforme (GBM).
Li J; Tang H; Zhang Y; Tang C; Li B; Wang Y; Gao Z; Luo P; Yin A; Wang X; Cheng G; Fei Z
PLoS One; 2013; 8(11):e81258. PubMed ID: 24278406
[TBL] [Abstract][Full Text] [Related]
22. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
23. The NF-κB RelB protein is an oncogenic driver of mesenchymal glioma.
Lee DW; Ramakrishnan D; Valenta J; Parney IF; Bayless KJ; Sitcheran R
PLoS One; 2013; 8(2):e57489. PubMed ID: 23451236
[TBL] [Abstract][Full Text] [Related]
24. Elucidating the cellular uptake mechanisms of heptamethine cyanine dye analogues for their use as an anticancer drug-carrier molecule for the treatment of glioblastoma.
Cooper E; Choi PJ; Hwang K; Nam KM; Kim CY; Shaban T; Schweder P; Mee E; Correia J; Turner C; Faull RLM; Denny WA; Noguchi K; Dragunow M; Jose J; Park TI
Chem Biol Drug Des; 2023 Mar; 101(3):696-716. PubMed ID: 36323652
[TBL] [Abstract][Full Text] [Related]
25. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB.
Tchoghandjian A; Jennewein C; Eckhardt I; Momma S; Figarella-Branger D; Fulda S
Cell Death Differ; 2014 May; 21(5):735-47. PubMed ID: 24488095
[TBL] [Abstract][Full Text] [Related]
26. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
27. Iruplinalkib (WX‑0593), a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in preclinical models for non-small cell lung cancer.
Yang Y; Zheng Q; Wang X; Zhao S; Huang W; Jia L; Ma C; Liu S; Zhang Y; Xin Q; Sun Y; Zheng S
Invest New Drugs; 2023 Apr; 41(2):254-266. PubMed ID: 37036582
[TBL] [Abstract][Full Text] [Related]
28. Targeting NF-κB in glioblastoma: A therapeutic approach.
Friedmann-Morvinski D; Narasimamurthy R; Xia Y; Myskiw C; Soda Y; Verma IM
Sci Adv; 2016 Jan; 2(1):e1501292. PubMed ID: 26824076
[TBL] [Abstract][Full Text] [Related]
29. The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma.
Shi P; Xu J; Cui H
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373484
[TBL] [Abstract][Full Text] [Related]
30. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
32. MDA-9/syntenin is a key regulator of glioma pathogenesis.
Kegelman TP; Das SK; Hu B; Bacolod MD; Fuller CE; Menezes ME; Emdad L; Dasgupta S; Baldwin AS; Bruce JN; Dent P; Pellecchia M; Sarkar D; Fisher PB
Neuro Oncol; 2014 Jan; 16(1):50-61. PubMed ID: 24305713
[TBL] [Abstract][Full Text] [Related]
33. Linarin suppresses glioma through inhibition of NF-κB/p65 and up-regulating p53 expression in vitro and in vivo.
Zhen ZG; Ren SH; Ji HM; Ma JH; Ding XM; Feng FQ; Chen SL; Zou P; Ren JR; Jia L
Biomed Pharmacother; 2017 Nov; 95():363-374. PubMed ID: 28858735
[TBL] [Abstract][Full Text] [Related]
34. TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of IκBα.
Ji J; Ding K; Luo T; Zhang X; Chen A; Zhang D; Li G; Thorsen F; Huang B; Li X; Wang J
Cell Death Differ; 2021 Jan; 28(1):367-381. PubMed ID: 32814880
[TBL] [Abstract][Full Text] [Related]
35. Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Sai K; Li WY; Chen YS; Wang J; Guan S; Yang QY; Guo CC; Mou YG; Li WP; Chen ZP
Am J Chin Med; 2014; 42(2):485-503. PubMed ID: 24707876
[TBL] [Abstract][Full Text] [Related]
36. SLFN11 negatively regulates non-canonical NFkB signaling to promote glioblastoma progression.
Fischietti M; Eckerdt F; Perez RE; Guillen Magaña JN; Mazewski C; Ho S; Gonzalez C; Streich LD; Beauchamp EM; Heimberger AB; Baran AH; Yue F; James CD; Platanias LC
Cancer Res Commun; 2022 Sep; 2(9):966-978. PubMed ID: 36382088
[TBL] [Abstract][Full Text] [Related]
37. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus.
Shukla S; Pia Patric IR; Thinagararjan S; Srinivasan S; Mondal B; Hegde AS; Chandramouli BA; Santosh V; Arivazhagan A; Somasundaram K
Cancer Res; 2013 Nov; 73(22):6563-73. PubMed ID: 24078801
[TBL] [Abstract][Full Text] [Related]
38. MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF-κB activation.
Liu X; Yue C; Shi L; Liu G; Cao Q; Shan Q; Wang Y; Chen X; Li H; Wang J; Gao S; Niu M; Yu R
J Cell Mol Med; 2020 Jul; 24(13):7550-7562. PubMed ID: 32452133
[TBL] [Abstract][Full Text] [Related]
39. Micellar formulations of Crizotinib and Dasatinib in the management of glioblastoma multiforme.
Greish K; Jasim A; Parayath N; Abdelghany S; Alkhateeb A; Taurin S; Nehoff H
J Drug Target; 2018 Sep; 26(8):692-708. PubMed ID: 29251531
[TBL] [Abstract][Full Text] [Related]
40. Nix protein positively regulates NF-κB activation in gliomas.
Lu Y; Wang L; He M; Huang W; Li H; Wang Y; Kong J; Qi S; Ouyang J; Qiu X
PLoS One; 2012; 7(9):e44559. PubMed ID: 22984526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
